Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis.

International journal of molecular sciences - 24 Mar 2021

Epstein Shochet Gali, Bardenstein-Wald Becky, McElroy Mary, Kukuy Andrew, Surber Mark, Edelstein Evgeny, Pertzov Barak, Kramer Mordechai Reuven, Shitrit David

Abstract excerpt

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis. The IPF-conditioned matrix (IPF-CM) system enables the study of matrix-fibroblast interplay. While effective at slowing fibrosis, nintedanib has limitations and the mechanism is not fully elucidated. In the current work, we explored the underlying signaling pathways and characterized nintedanib involvement in the IPF-CM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bleomycin
Share to Fibroblasts

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypoxia-Inducible Factor 1, alpha Subunit

Share to Idiopathic Pulmonary Fibrosis

Share to Immunohistochemistry

Share to Indoles

Share to RNA-Seq

Source

Open in PubMed Open full text

Identifiers

PMID: 33805152
DOI: 10.3390/ijms22073331
PMCID: PMC8078165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis.PMID 33805152Read ↗

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.Semantic proximity Read ↗

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.Semantic proximity Read ↗

A new perspective on idiopathic pulmonary fibrosis research: From multi-dimensional mechanistic exploration to advances in precision therapy.Semantic proximity Read ↗

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary FibrosisSemantic proximity Read ↗

Fibrotic human lung extracellular matrix as a disease-specific substrate for 3D <i>in-vitro</i> models of pulmonary fibrosisSemantic proximity Read ↗

Hypoxia Inducible Factor-1α in Pulmonary Fibrosis: A Promising Therapeutic TargetSemantic proximity Read ↗

Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.Semantic proximity Read ↗

Recent advances in understanding idiopathic pulmonary fibrosisSemantic proximity Read ↗

RNA-sequencing comparison of pneumonectomy and bleomycin reveals anti-fibrotic mechanisms of lung fibroblastsSemantic proximity Read ↗

Comparative Expression Profiling in Pulmonary Fibrosis Suggests a Role of Hypoxia-inducible Factor-1α in Disease PathogenesisSemantic proximity Read ↗

Expression profiles of nintedanib-targeting molecules in progressive fibrotic interstitial lung diseases (non-IPF-PF) and IPFSemantic proximity Read ↗

Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.